CX-516

Summary

CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and had been undergoing development by a collaboration between Cortex, Shire, and Servier. It was studied as a potential treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD.

CX-516
Pharmacokinetic data
Elimination half-life45 minutes
Identifiers
  • 6-(Piperidin-1-ylcarbonyl)quinoxaline
CAS Number
  • 154235-83-3 checkY
PubChem CID
  • 148184
IUPHAR/BPS
  • 4165
ChemSpider
  • 130635 checkY
UNII
  • Z5QU38B4V9
KEGG
  • C13675 checkY
ChEMBL
  • ChEMBL136800 checkY
CompTox Dashboard (EPA)
  • DTXSID70165574 Edit this at Wikidata
ECHA InfoCard100.237.047 Edit this at Wikidata
Chemical and physical data
FormulaC14H15N3O
Molar mass241.294 g·mol−1
3D model (JSmol)
  • Interactive image
  • O=C(c2cc1nccnc1cc2)N3CCCCC3
  • InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2 checkY
  • Key:ANDGGVOPIJEHOF-UHFFFAOYSA-N checkY
  (verify)

CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to.

See also edit

References edit

  • Danysz W (July 2002). "CX-516 Cortex pharmaceuticals". Current Opinion in Investigational Drugs. 3 (7): 1081–8. PMID 12186271.